Company: ACBM
Filing Date: 2025-11-10
Form Type: 10-Q
Source: 0001640334-25-001999
Chunk: 37

Company: ACRO BIOMEDICAL CO., LTD.
Filing Date: 2025-11-10
Form: 10-Q
Item: Item 8
Chunk 37
---
31, 2022, along with the absence of an active market for our stock and our stock being traded on the OTC Market Group’s Pink Limited Market.  Our common stock was previously listed on the OTC Market Group’s Expert Market, as a result of which our common stock was not eligible for proprietary broker-dealer quotes.  As a result, there are no market makers for our common stock.  At present, our stock is not eligible for proprietary broker-dealer quotations and all quotes reflect unsolicited customer orders.  Unsolicited only stocks have a higher risk of wider spreads, increased volatility, and price dislocations. Investors may have difficulty selling this stock. An initial review by a broker-dealer under SEC Rule15c2-11 is required for brokers to publish competing quotes and provide continuous market making.  Accordingly, there are no published quotes for our common stock and we cannot assure you that a broker-dealer will take the necessary steps to make a market in our common stock. This lack of a trading market for our common stock together with risk related to political and legal situation in Hong Kong, may be difficult for us to raise funds in the equity market, and, if we are able to raise funds our stockholders may suffer significant dilution. Our primary source of funds for the years ended December 31, 2024 and 2023 and the nine months ended September 30, 2025 has been advances from a minority stockholder. This stockholder has continued to be our principal source of funds.  We cannot assure you that he will continue to provide funding for us.

To the extent that we implement our business plan, we anticipate that we will incur marketing and other expenses without any assurance that such expenses will generate any significant revenue, cash flow from operations or net income. Because of our cash position, we may seek to use equity-based compensation for our employees and independent contractors.  Because of our low cash position, we may rely on loans from stockholders or related parties, although we do not have any agreements or understandings at this time, and we may issue equity to attract employees and consultants to help us develop our business plan.   Because we are quoted on the Pink Limited Market, our common stock is an unsolicited only stock and there are no market makers for our common stock, potential employees or consultants may be reluctant to accept common stock as compensation.  We cannot assure you that we will be able to develop or market products, in which case we may continue to be unable to generate revenue.